Back to Search

Torvutatug Samrotecan Plus Bevacizumab for Ovarian Cancer

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

Recruiting Phase 3 Interventional Study
Epithelial Ovarian Cancer
More trials: Cancer clinical trials· Cancer trials in Florida
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
950 (estimated)
Sponsor
AstraZeneca · Industry
Who this trial is looking for

This trial is looking for women with advanced epithelial ovarian cancer who have already received some treatments. Participants will receive a new combination therapy after their initial chemotherapy.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with advanced epithelial high-grade ovarian cancer.
  • I have completed at least 6 cycles of first-line platinum-based chemotherapy.
  • I have received at least 3 cycles of bevacizumab with my last chemotherapy cycles.
  • I have completed surgery to remove my tumor, or my cancer cannot be surgically removed.
  • I do not have worsening disease after my initial treatments.
  • I have a tumor that is HRD negative.

You may not be able to join if

  • I have tumors that are not epithelial, borderline tumors, or low-grade tumors.
  • I have a history of lung problems that required steroids or extra oxygen.
  • I have a non-healing wound, an active ulcer, or a broken bone.
  • I have signs of a bowel obstruction that is still ongoing.
  • I have previously received any specific targeted therapies.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with Homologous Recombination Deficient (HRD) negative advanced ovarian cancer.

Trial Locations

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: * Participants with newly diagnosed FIGO Stage III/IV, histologically confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma * Provision of an archival FFPE tumour sample * Participants who have completed at least 6 cycles and a maximum of 8 …
Contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

CONTACT

NCT ID: NCT07851025 Source: ClinicalTrials.gov